S
Shashikant Juvekar
Researcher at Tata Memorial Hospital
Publications - 38
Citations - 857
Shashikant Juvekar is an academic researcher from Tata Memorial Hospital. The author has contributed to research in topics: Induction chemotherapy & Head and neck cancer. The author has an hindex of 12, co-authored 35 publications receiving 636 citations. Previous affiliations of Shashikant Juvekar include Homi Bhabha National Institute.
Papers
More filters
Journal ArticleDOI
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial
Vanita Noronha,Amit Joshi,Vijay Patil,Jai Prakash Agarwal,Sarbani Ghosh-Laskar,Ashwini Budrukkar,Vedang Murthy,Tejpal Gupta,Anil K. D'Cruz,Shripad Banavali,Prathamesh S. Pai,Pankaj Chaturvedi,Devendra Chaukar,Nikhil Pande,Arun Chandrasekharan,Vikas Talreja,Dilip Harindran Vallathol,Vijayalakshmi Mathrudev,Aparna Manjrekar,Kamesh Maske,Arati Sanjay Bhelekar,Kavita Nawale,Sadhana Kannan,Vikram Gota,Atanu Bhattacharjee,Shubhada Kane,Shashikant Juvekar,Kumar Prabhash +27 more
TL;DR: Once-every-3-weeks cisplatin at 100 mg/m2 resulted in superior LRC, albeit with more toxicity, than did once-a-week cisplinatin at 30 mg/ m2, and should remain the preferred chemoradiotherapy regimen for LAHNSCC in the adjuvant setting.
Journal ArticleDOI
CT–guided percutaneous core needle biopsy in deep seated musculoskeletal lesions: a prospective study of 128 cases
Ajay Puri,V. U. Shingade,Manish Agarwal,Chetan Anchan,Shashikant Juvekar,Subhash Desai,Nirmala A. Jambhekar +6 more
TL;DR: CT-guided core needle biopsy is a safe, easy, and effective technique for the evaluation of deep-seated musculoskeletal lesions, with a high rate of diagnostic yield and accuracy.
Journal ArticleDOI
Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers
V.M. Patil,Kumar Prabhash,Vanita Noronha,Amit Joshi,V Muddu,Sachin Dhumal,Supreeta Arya,Shashikant Juvekar,Pankaj Chaturvedi,Devendra Chaukar,Prathamesh S. Pai,S. V. Kane,Asawari Patil,J.P. Agarwal,S. Ghosh-Lashkar,Anil K. D'Cruz +15 more
TL;DR: NACT led to successful resection and improved overall survival in a significant proportion of technically unresectable oral-cancer patients.
Journal ArticleDOI
A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer
Vijay Patil,Vanita Noronha,Amit Joshi,Jai Prakash Agarwal,Sarbani Ghosh-Laskar,Ashwini Budrukkar,Vedang Murthy,Tejpal Gupta,Manoj B. Mahimkar,Shashikant Juvekar,Supreeta Arya,Abhishek Mahajan,Archi Agarwal,Nilendu Purandare,Venkatesh Rangarajan,Arun Balaji,Sameer Chaudhari,Shripad Banavali,Sadhana Kannan,Atanu Bhattacharjee,Anil K. D'Cruz,Pankaj Chaturvedi,Prathamesh S. Pai,Devendra Chaukar,Gouri Pantvaidya,Deepa Nair,Sudhir Nair,Anuja Deshmukh,Shivakumar Thiagarajan,Vijayalakshmi Mathrudev,Aparna Manjrekar,Sachin Dhumal,Kamesh Maske,Arti Bhelekar,Kavita Nawale,Arun Chandrasekharan,Nikhil Pande,Alok Goel,Vikas Talreja,Vijai Simha,Sujay Srinivas,Rohit Swami,Dilip Harindran Vallathol,Hollis Dsouza,Sameer Shrirangwar,Siddharth Turkar,George Abraham,Aditi Harsh Thanky,Usha Patel,Manish Kumar Pandey,Kumar Prabhash +50 more
TL;DR: Because the addition of nimotuzumab to chemoradiation in patients with locally advanced head and neck cancer improved outcomes in a phase 2 study, the authors conducted a phase 3 study to confirm these findings.
Journal ArticleDOI
A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck.
Vijay Patil,Vanita Noronha,Amit Joshi,Vamshi Muddu,Sachin Dhumal,Bharatsingh Bhosale,Supreeta Arya,Shashikant Juvekar,Shripad Banavali,Anil K. D'Cruz,Atanu Bhattacharjee,Kumar Prabhash +11 more
TL;DR: Oral metronomic chemotherapy has significantly better PFS and OS than single agent platinum in the palliative setting and may be safer and more effective in this setting.